



## Calithera Biosciences to Present at the JMP Securities Life Sciences Conference 2015

June 16, 2015

SOUTH SAN FRANCISCO, Calif., June 16, 2015 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced its participation at the JMP Securities Life Sciences Conference 2015. Susan M. Molineaux, Ph.D., Founder, President and Chief Executive, will present on Tuesday, June 23, 2015 at 9:30 a.m. Eastern Time at The St. Regis Hotel in New York, NY. The presentation will be webcast live and available for replay for up to 30 days at [www.calithera.com](http://www.calithera.com) under the tab Investors.

### About Calithera

Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Calithera's lead product candidate, CB-839, is currently being evaluated in three Phase 1 clinical trials in solid and hematological cancers. Calithera is headquartered in South San Francisco. For more information about Calithera, please visit [www.calithera.com](http://www.calithera.com).

### Forward Looking Statements

This news release contains forward-looking statements by Calithera that involve risks and uncertainties. Actual results may differ from Calithera's expectations and important factors that could cause actual results to differ materially. Calithera's product candidates may not progress through clinical development or receive required regulatory approvals within expected timelines or at all. In addition, clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release. Such product candidates may not be beneficial to patients or successfully commercialized. The failure to meet expectations with respect to any of the foregoing matters may have a negative effect on Calithera's stock price. Additional information concerning these and other risk factors affecting Calithera's business can be found in Calithera's Quarterly Report on Form 10-Q for the quarter ended March 31, 2015 filed with the Securities and Exchange Commission on May 11, 2015, and other periodic filings with the Securities and Exchange Commission at [www.sec.gov](http://www.sec.gov). These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, Calithera disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.

CONTACT: Jennifer McNealey  
[ir@Calithera.com](mailto:ir@Calithera.com)  
650-870-1071

[Calithera Biosciences](#)

Calithera Biosciences, Inc.